Dr. Brandon R. Weckbaugh
Claim this profileCotton O'Neil Cancer Center / Stormont Vail Health
Studies Cancer
Studies Renal Cell Carcinoma
2 reported clinical trials
3 drugs studied
Affiliated Hospitals
Clinical Trials Brandon R. Weckbaugh is currently running
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of cancer cells. Combination therapy with atezolizumab and cabozantinib may shrink the cancer and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
Text-Based Smoking Cessation Program
for Rural Cancer Survivors
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Recruiting2 awards Phase 3
More about Brandon R. Weckbaugh
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Brandon R. Weckbaugh has experience with
- Text-Based Cessation Intervention
- Atezolizumab
- Cabozantinib S-malate
Breakdown of trials Brandon R. Weckbaugh has run
Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brandon R. Weckbaugh specialize in?
Brandon R. Weckbaugh focuses on Cancer and Renal Cell Carcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Brandon R. Weckbaugh currently recruiting for clinical trials?
Yes, Brandon R. Weckbaugh is currently recruiting for 2 clinical trials in Topeka Kansas. If you're interested in participating, you should apply.
Are there any treatments that Brandon R. Weckbaugh has studied deeply?
Yes, Brandon R. Weckbaugh has studied treatments such as Text-Based Cessation Intervention, Atezolizumab, Cabozantinib S-malate.
What is the best way to schedule an appointment with Brandon R. Weckbaugh?
Apply for one of the trials that Brandon R. Weckbaugh is conducting.
What is the office address of Brandon R. Weckbaugh?
The office of Brandon R. Weckbaugh is located at: Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka, Kansas 66606 United States. This is the address for their practice at the Cotton O'Neil Cancer Center / Stormont Vail Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.